Last updated: February 20, 2026
What is the drug identified by NDC 00078-0502?
The National Drug Code (NDC) 00078-0502 corresponds to Tecentriq (atezolizumab), a monoclonal antibody developed by Genentech (a Roche subsidiary). It is used in cancer immunotherapy, approved primarily for non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and urothelial carcinoma.
Market Landscape
Competitive Position
Tecentriq holds a significant share within the immune checkpoint inhibitors market, competing primarily with Merck's Keytruda (pembrolizumab) and Bristol-Myers Squibb's Opdivo (nivolumab). The drug benefits from multiple FDA approvals and ongoing clinical trials, expanding its potential indications.
Market Size and Demand Drivers
Key Market Dynamics
Price Projections
Short-term (1-2 years)
-
Current Price Point:
- WAC for Tecentriq remains stable; approximately $11,000 per dose.
- Average treatment courses range from 4 to 6 doses, implying a per-patient cost of $44,000 to $66,000.
-
Projected Trends:
- Slight price increases (~2-3%) expected, aligned with inflation and value-based pricing adjustments.
- Discounting policies and negotiations may reduce average net prices by 10-20%.
Medium-term (3-5 years)
- Price Trends:
- No significant increase expected, barring regulatory changes or new patent exclusivities.
- Biosimilar competition is unlikely in the short term, maintaining high pricing power.
- Possible price stabilization or slight reductions due to increased market competition and pressure from payers.
Long-term (5+ years)
Quantitative Summary
| Timeframe |
Expected Price Trend |
Notes |
| 0-2 years |
Marginal increases (~2-3%) |
Stable pricing with slight inflation |
| 3-5 years |
Potential stabilization or slight decline (~5-10%) |
Due to payer negotiations and market dynamics |
| 5+ years |
Possible decrease (40-60%) with biosimilar entry |
Patent expiry and biosimilar market penetration |
Regulatory and Policy Factors Affecting Pricing
- U.S. FDA approvals expand indications, supporting continued high prices.
- Patent protections are critical; expiry around 2028-2030 signals upcoming price pressure.
- Health policy focus on value-based pricing could influence net prices.
- International pricing varies; many regions implement price controls or negotiations.
Key Takeaways
- Tecentriq (NDC 00078-0502) remains a high-priced immunotherapy with growing demand.
- Stable pricing in the short term, with minor increases driven by inflation and value-based arrangements.
- Long-term price reductions likely following patent expiration and biosimilar competition.
- Market share is driven by clinical efficacy, approval expansion, and reimbursement policies.
FAQs
1. How does Tecentriq’s pricing compare to its competitors?
Tecentriq's prices are similar to other PD-L1 inhibitors like Imfinzi ($11,500 per dose) and slightly higher than Keytruda ($10,000 per dose). Competitor pricing varies by indication and region.
2. What are the main factors influencing Tecentriq’s future price?
Patent expiration, biosimilar development, regulatory approvals, and payer negotiations shape future prices.
3. Are biosimilar entry expected soon?
Biosimilar development faces scientific and regulatory hurdles, delaying entry until at least 2028 or later.
4. How does reimbursement affect Tecentriq’s net price?
Negotiated discounts and rebates can reduce net prices by 10-20%, depending on market and payor policies.
5. What is the impact of new indications on Tecentriq’s pricing?
Additional approved indications can justify higher pricing and extend patent exclusivity, sustaining revenue streams.
Citations:
[1] U.S. Food and Drug Administration. (2022). Tecentriq (atezolizumab) approvals and label updates.
[2] IQVIA. (2022). Global oncology market sales data.
[3] EvaluatePharma. (2022). Oncology drug market forecasts.
[4] FDA. (2024). Patent protections and biosimilar approval timelines.
[5] Medicare and private insurer reimbursement policies.
